1 ASX artificial intelligence (AI) stock that could help turbocharge your portfolio

Analysts at Goldman Sachs are raving about this AI stock.

| More on:
A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's no denying that artificial intelligence (AI) is going to revolutionise the world of business.

However, some businesses stand to benefit more than others. And few more so than Pro Medicus Limited (ASX: PME).

At present, it is known as a health imaging technology stock. But given just how much AI could impact its operations, it probably won't be long until it is known as an ASX AI stock.

Why is Pro Medicus an ASX AI stock?

The team at Goldman Sachs was running the rule over the company last week and highlighted its enormous opportunity with AI.

But firstly, as a reminder, let's just look at what Pro Medicus actually is today.

It is a leading provider of radiology information systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation solutions across the world.

Its key offering is the Visage 7 Enterprise Imaging Platform. It provides a fast, clinically rich, and highly scalable growth platform that is deliverable entirely from the cloud or on premise.

This disruptive platform is regarded as the best in its class and has been winning huge long-term contracts from some of the most highly regarded healthcare institutions in the world. This has led to explosive earnings growth over the last decade.

Now, let's get back to what makes this an AI stock. Goldman explained in its note this week, it said:

AI opens an incremental US$620mn TAM today (growing at a +34.7% CAGR) with radiology receiving the majority (c.80%) of recent FDA AI algorithm clearance. We believe PME is well positioned to take share as the incumbent viewing platform across many large, and likely early adopters of new technology.

PME is generating revenue from its Visage breast density AI algorithm (developed via a partnership with Yale) today, and we see the potential value for AI to be significant with adoption driven by improved accuracy and clinical outcomes. We forecast AI to comprise 9% of PME's revenue by FY30E (from <1% in FY25E), with upside if PME achieves faster AI attach penetration, higher price per scan, and a greater proportion of algorithms developed in-house where no royalties are paid to a partner.

Is it a buy?

Goldman thinks Pro Medicus is an AI stock to buy right now.

Last week, it initiated coverage on the company's shares with a buy rating and a $134.00 price target.

This implies a potential upside of approximately 30% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A corporate female wearing glasses looks intently at a virtual reality screen with shapes and lights representing Block shares going up today
Growth Shares

Forget Nvidia: This ASX growth stock is poised for its own bull run

I think this ASX growth stock could beat the phenomenal share price gains posted by Nvidia.

Read more »

flying asx share price represented by man flying remote control drone
Share Gainers

Up 246% in a year, here's why the Droneshield share price is racing higher again today

ASX investors are sending the Droneshield share price soaring today. But why?

Read more »

a group of people sit around a computer in an office environment.
Technology Shares

Is this ASX 200 tech stock in the buy zone following its results?

Is now a good time to snap up this top tech stock? Let's see what a leading broker is saying.

Read more »

A man sees some good news on his phone and gives a little cheer.
Technology Shares

Why are Brainchip shares racing higher after its AGM?

This struggling semiconductor stock is having a good session. But why?

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

ASX 200 tech stock lifts off on another record-setting half-year profit

Investors are bidding up the ASX 200 tech company following its half-year results.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Technology Shares

Buy this ASX tech stock for a 26% return

Bell Potter is saying good things about this tech stock and sees it as a potential takeover target.

Read more »

Man smiling at a laptop because of a rising share price.
Technology Shares

Up 53% in a month, how Nuix shares are winning back investors

Is this ASX tech share back in the good books of investors?

Read more »

Sports fans looking at smart phone representing surging pointsbet share price
Share Gainers

Guess which ASX All Ords share just rocketed 25% on an earnings upgrade

Investors are bidding up the ASX All Ords share following an improved FY 2024 earnings outlook.

Read more »